Exact Sciences Corporation has entered into an exclusive licensing agreement with Freenome, a biotechnology company specializing in early cancer detection. Under this partnership, Exact Sciences will acquire exclusive rights in the United States to Freenome's blood-based colorectal cancer screening tests. This collaboration aims to enhance Exact Sciences' leadership in cancer screening by introducing blood-based options, alongside its existing Cologuard Plus test, to address the needs of over 50 million unscreened Americans. The agreement includes Exact Sciences' commitment to invest $20 million annually in joint R&D efforts over three years and a $50 million purchase of a senior convertible note from Freenome. Additionally, Exact Sciences will provide milestone payments contingent on FDA approvals and performance benchmarks, with potential payouts totaling up to $700 million. This partnership is expected to expedite the delivery of advanced cancer screening technologies to patients, leveraging Exact Sciences' extensive commercial network and expertise.